Home Message from CEO About US Business Operations Features of Our Technology Contact
Site Map Japanese  
References

・Uenaka, A., Wada, H., Isobe, M., Saika, T., Tsuji, K., Sato, E., Sato, S., Noguchi, Y., Kawabata, R., Yasuda, T., Doki, Y., Kumon, H,. Iwatsuki, K., Shiku, H., Monden, M., Jungbluth, A., Ritter, G., Murphy, R., Hoffman, E., Old, LJ. and Nakayama, E. : T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immunity Vol. 7, p9, April 19, 2007

・Kitano, S., Kageyama, S., Nagata, Y., Miyahara, Y., Hiasa, A., Naota, H., Okumura, S., Imai, H., Shiraishi, T., Masuya, M., Nishikawa, M., Sunamoto, J., Akiyoshi, K., Kanematsu, T., Scott, AM., Murphy, R., Hoffman, EW., Old, LJ.,and Shiku, H. : HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan. Clin. Cancer Res. 2006; 12(24), 7397-7405, December 15, 2006

・Nishikawa, H., Kato, T., Takawa, I., Saito, K., Ikeda, H., Kuribayashi, K., Allen, P.M., Schreiber, R.D., Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. J.Exp.Med. 201(5)681-686, 2005.

・Nishikawa, H., Kato, T., Tawara, I., Ikeda, H., Kuribayashi, K., Allen, P.M., Schreiber, R.D., Old, L.J., and Shiku, H. : IFN-γcontrols the generation/activation of CD4+ CD25+ regulatory T cells in antitumor Immune response. J. Immunology 175, 4433-4440, 2005.

・Miyahara, Y., Naota, H., Wang, L., Hiasa, A., Goto, M., Watanabe, M., Kitano, S., Okumura, S., Takemitsu, T., Yuta, A., Majima, Y., Lemonnier, F. A., Boon and Shiku, H. : Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ lines, MAGE-A4 and SAGE. Clin. Cancer Res. 2005;11(15), 5581-5589, 2005.

・Nishikawa, H., Kato, T., Tawara, I., Takemitsu, T., Saito, K., Wang, L., Ikarashi, Y., Wakasugi, H., Nakayama, T., Taniguchi, M., Kuribayashi, K., Old, L.J., and Shiku, H. : Accelerated chemically induced tumor development mediated by CD4+ CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA. 102:9253-9257, 2005.

・Nishikawa, H., Kato, T., Tanida, K., Hiasa, A., Tawara, I., Ikeda, H., Ikarashi, Y., Wakasugi, H., Kronenberg, M., Nakayama, T., Taniguchi, M., Kuribayashi, K., Old, L.J., and Shiku, H. : CD4 +CD25 +T cells responding to serologically defined autoantigens suppress antitumor immune response. Proc. Natl. Acad. Sci. USA. 100:10902-10906, 2003.

・Wang L, Miyahara Y, Kato T, Wang L, Aota T, Kuribayashi K, Shiku H., Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine. Cancer Immun. Nov 21;3:16,2003

・Shiku, H., Importance of CD4+ helper T-cells in antitumor immunity. Int J Hematol. 77:435-8, 2003.

・Ishihara, M., Tawara, I., Wang, L., Takahashi, Y., and Shiku, H. : Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts. International J. Oncology 22:1135-1139, 2003.

・Ikuta,Y., Katayama, N.,Wang,L., Okugawa,T., Takahashi,Y., Schmitt,M., Gu,X., Watanabe,M., Akiyoshi,K., Nakamura,H., Kuribayashi,K., Sunamoto,J. and Shiku,H. :Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 99:3717-3724, 2002.

・Mukai, K., Yasutomi, Y., Watanabe, M., Kenjo, A., Aota, T., Wang, L., Nishikawa, H., Ishihara, M., Fujita, T., Kuribayashi, K. and Shiku, H .: HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations. Gene Ther. 9:879-888, 2002.

・Nishikawa, H., Tanida, K., Ikeda, H., Sakakura, M., Miyahara, Y., Aota, T., Mukai, K., Watanabe, M., Kuribayashi, K., Old, LJ. and Shiku, H. : Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor specific immunity. Proc. Natl. Acad. Sci. USA. 98:14571-14576, 2001.

・Shiku, H., Wang, L., Ikuta, Y., Okuguwa, T., Schmidt, M., Gu, X., Akiyoshi, K., Sunamoto, J., Nakamura, H. :Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother. Pharmacol. 46(Suppl) S77-S82, 2000.

・Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L, Ikeda H, Watanabe M, Imai S, Shiku H., A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Int J Cancer. 15;87(4):553-8,2000

・Okugawa, T., Ikuta, Y., Takahashi, Y., Obata, H., Tanida, K., Watanabe, M., Imai, S., Furugen, R., Nagata, Y., Toyoda, N. and Shiku, H. : A novel human HER2-derived peptide homologous to the mouse K(d) -restricted tumor rejection antigen can induce HLA-A24 restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur. J. Immunol. 30 : 3338-3346, 2000.

・Gu, X., Schmidt, M., Hiasa, A., Nagata, Y., Ikeda, H., Sasaki, Y., Akiyoshi, K., Sunamoto, J., Nakamura, H., Kuribayashi, K. and Shiku, H. : A novel hydrophobized polysaccharide/oncoprotein complex vaccine Induces in vitro and in vivo cellular and humoral Immune responses against HER2-expressing murine sarcomas. Cancer Res. 58: 3385-3390, 1998.

・Nagata, Y., Furugen, R., Hiasa , A., Ikeda, H., Ohta , N., Furukawa, K., Nakamura, H., Furukawa, K., Kanematsu, T. and Shiku, H. : Peptides derived from a wild type murine proto- oncogene c-erB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol . 159: 1336-1343, 1997.

・Ikeda, H., Ohta, N., Furukawa, K., Miyazaki, H., Wang, L., Kuribayashi, K., Old, L.J. and Shiku, H. : Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA 94: 6375-6379, 1997.

【 Back 】